A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Learn more about:
Related Clinical Trial
Retrospective Register for Uveal Melanoma
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
Adjuvant Melatonin for Uveal Melanoma
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma
A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
Managed Access Program Supporting Patient Access to Tebentafusp
Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients
Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
A Prospective Natural History Study in Uveal Melanoma
Uveal Melanoma and Brachytheraphy: Long-term Outcomes.
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours
Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
A Study of PLX2853 in Advanced Malignancies.
Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)
Treatment Of Radiation Retinopathy Trial
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Study in Subjects With Small Primary Choroidal Melanoma
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes
Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Vascular Response to Brachytherapy Using Functional OCT
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy
Intermittent Selumetinib for Uveal Melanoma
Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
New Biopsy Technique for Uveal Melanoma
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Treatment With Intravitreal Avastin for Large Uveal Melanomas